相关实验视频

Updated: Mar 6, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在多学科治疗后的长期存活率,包括对复发性周围性胆管癌的杜尔瓦卢马布治疗

Takashi Miyata¹, Taigo Nagayama², Hisashi Nishiki²

¹Department of General and Digestive Surgery, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan. ryutami5383917@gmail.com.

Clinical journal of gastroenterology

|March 4, 2026

概括

复发的周围性胆管癌可以实现长期的生存. 将化疗与免疫检查点抑制剂 (ICI) 结合在一起,导致患有晚期疾病的患者的完整反应.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
免疫治疗是一种免疫疗法.

背景情况:

周围胆管癌具有侵略性,在手术后经常复发.
在复发性疾病的标准化疗中,持久生存是罕见的.
免疫检查点抑制剂 (ICI) 在晚期胆道癌症中表现有前途.

研究的目的:

报告一个用新型组合疗法治疗的复发性周围性胆管癌病例.
突出免疫检查点抑制剂在管理晚期胆道癌症方面的潜力.

主要方法:

一名61岁的男性患有IVA阶段的外性胆管癌,接受了手术.
复发被治疗为gemcitabine加 cisplatin (GC),S-1和质子束疗法.
随后的肝脏内转移被用GC-durvalumab (GCD) 治疗.

主要成果:

患者在GCD治疗2年内实现了放射性完整反应.
在复发后的53个月内观察到持续的疾病控制.
仅报告了1级皮肤毒性.

结论:

免疫检查点抑制剂可以在复发的周围性胆管癌中有效.
结合ICI的多学科治疗策略可能会导致长期的生存.
这种情况表明,在晚期胆道癌症中,临床完整反应和持续的疾病控制的可能性很大.

关键词:

临床完整反应的临床完整反应.免疫检查点抑制剂免疫检查点抑制剂多学科的治疗方法.周围的胆管癌 (Perihilar Cholangiocarcinoma) 是一种状胆管癌.

更多相关视频

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...